Abiopharma

🔍 Hack Andrew A. F. (Executive)

Company: Mersana Therapeutics, Inc. (MRSN)

Report Date: 2026-01-06

Detailed Transactions and Holdings:

• Sold 578 shares of Common Stock (Direct)
  Date: 2026-01-06 | Code: U | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 346,545 shares of Common Stock (Direct)
  Date: 2026-01-06 | Code: U | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F5
• Sold 2,460 shares of Stock Option (right to buy) at $9.0775 per share (Derivative)
  Date: 2026-01-06 | Code: D | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F3, F3, F3
• Sold 2,088 shares of Stock Option (right to buy) at $125.0 per share (Derivative)
  Date: 2026-01-06 | Code: D | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F4, F4, F4
• Sold 400 shares of Stock Option (right to buy) at $306.75 per share (Derivative)
  Date: 2026-01-06 | Code: D | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F4, F4, F4
• Sold 1,000 shares of Stock Option (right to buy) at $107.75 per share (Derivative)
  Date: 2026-01-06 | Code: D | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F4, F4, F4
• Sold 368 shares of Stock Option (right to buy) at $572.5 per share (Derivative)
  Date: 2026-01-06 | Code: D | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F4, F4, F4
• Sold 118 shares of Stock Option (right to buy) at $527.25 per share (Derivative)
  Date: 2026-01-06 | Code: D | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F4, F4, F4
• Sold 1,002 shares of Stock Option (right to buy) at $372.5 per share (Derivative)
  Date: 2026-01-06 | Code: D | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F4, F4, F4
• Sold 439 shares of Stock Option (right to buy) at $161.0 per share (Derivative)
  Date: 2026-01-06 | Code: D | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F4, F4, F4
• Sold 1,800 shares of Stock Option (right to buy) at $90.5 per share (Derivative)
  Date: 2026-01-06 | Code: D | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F4, F4, F4
• Sold 734 shares of Stock Option (right to buy) at $216.0 per share (Derivative)
  Date: 2026-01-06 | Code: D | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F4, F4, F4
• Sold 2,200 shares of Stock Option (right to buy) at $56.5 per share (Derivative)
  Date: 2026-01-06 | Code: D | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F4, F4, F4

Footnotes:

• F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Day One Biopharmaceuticals, Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. ("Purchaser"), dated as of November 12, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Upfront Cash Consideration"), plus (ii) one non-tradeable contingent value right per Share (each, a "CVR"),
• F2: (continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
• F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option.
• F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
• F5: Represents shares of Common Stock held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS II"), BCIP Life Sciences Associates, LP ("BCIPLS") and BCLS II Investco, LP ("BCLS II Investco" and, together with BCLS II and BCIPLS, the "Bain Capital Life Sciences Entities"). Bain Capital Life Sciences Investors, LLC ("BCLSI") (i) is the ultimate general partner of each of BCLS II and BCLS II Investco and (ii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. The Reporting Person is a Partner of BCLSI. As a result, the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by the Bain Capital Life Sciences Entities. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.